

# Author Index to Volume 29

- Abate, G., 28:119  
 Afghani, B., 29:73  
 Al-Ahdal, M.N., 27:69  
 Alexander, R., 28:75  
 Allen, S.D., 28:27  
 Altschuler, M., 29:107  
 Amand, R.S., 28:31  
 Anderson, D.E., 27:139  
 Appelbaum, P.C., 28:131  
 Arbeit, R.D., 27:147  
 Arduino, R., 29:107  
 Aristizabal, B.H., 29:103  
 Austin, E.F., 28:113
- Bajaksouzian, S., 28:105  
 Bale, M.J., 28:65  
 Balko, T.V., 28:179  
 Ballow, C.H., 29:173  
 Balows, A., 29:285  
 Barg, N.L., 27:147  
 Barrett, J.F., 27:85  
 Barrett, M.S., 27:129, 28:193  
 Barry, A.L., 28:27  
 Batts, D.H., 28:201  
 Bauman, M., 28:27  
 Beker, B., 28:149  
 Bello, H., 28:183  
 Benson, R.F., 28:1  
 Bergmann, J.S., 27:17, 27:113, 28:153  
 Biedenbach, D.J., 27:1, 27:7, 29:55  
 Billings, S.D., 29:281  
 Biondo, F.X., 28:123  
 Bissell, M.G., 27:13  
 Blahová, J., 29:129  
 Bliss, D.Z., 29:1  
 Bogaerts, J., 28:165  
 Bonilla, H.F., 27:147  
 Bonten, M.J.M., 27:103  
 Borek, A.P., 29:209  
 Bottone, E.J., 29:51  
 Brackman, M.A., 27:107  
 Brattebo, J., 29:111  
 Breiman, R.F., 28:1  
 Brown, S.D., 28:27  
 Bryant, M., 29:111  
 Buck, L.L., 29:139  
 Burman, W.J., 28:45
- Camp, C.J., 28:205  
 Canawati, H.N., 29:133, 29:233  
 Capo, A., 29:111  
 Caramello, P., 29:61  
 Carroll, K.C., 27:123  
 Cars, O., 27:29  
 Cassell, G.H., 27:117  
 Cassetta, I., 29:61  
 Chang, S.-C., 28:187  
 Chen, C., 29:167  
 Chen, Y.-C., 28:187  
 Chernomas, F., 29:11  
 Chipman, A., 29:111  
 Chow, A., 29:155  
 Cimolai, N., 28:61
- Clabots, C.R., 29:1  
 Classen, D., 27:123  
 Coffman, S.L., 28:211, 29:43  
 Cohen, R., 27:35  
 Cohen, S., 27:123  
 Cookson, S.T., 29:107  
 Cormican, M.G., 29:241  
 Corthey, C., 29:29  
 Couto, E., 29:29  
 Cowan, G.M., 29:121  
 Crabb, D.M., 27:117  
 Craig, W.A., 27:49
- Daley-Yates, P.T., 28:201  
 Daly, J., 27:123  
 Danforth, D., 29:155  
 Danziger, L.H., 29:167  
 Davis, T.E., 29:219, 29:281  
 Deguchi, T., 28:193  
 Deinhart, J.A., 29:173  
 De Mier, C.A., 29:29  
 Diekema, D.J., 29:147  
 Doern, G.V., 28:31, 29:265  
 Domínguez-Bello, M.G., 28:149  
 Dominquez, M., 28:183  
 Douboyas, J., 29:39  
 Dressel, D.C., 29:209  
 Dudley, M.N., 28:5  
 Duffy, L.B., 27:117  
 Duke, M.B., 29:73  
 Dulworth, J.K., 27:107  
 Dunn, D., 29:133
- Echeverria, P., 28:19  
 Edmond, M.B., 28:211, 29:95, 29:259  
 Edmund, M.B., 29:43  
 Eiland, J., 27:139  
 El-Farra, R., 29:133  
 Eliopoulos, G.M., 29:33  
 Erlich, S.S., 28:69  
 Ernst, E.J., 29:227  
 Ernst, M.E., 29:227  
 Erwin, M.E., 28:93, 29:95, 29:241
- Farinati, A., 29:29  
 Foleno, B.E., 27:85  
 Forno, B., 29:61  
 Forward, K.R., 29:215  
 Frighetto, L., 29:155  
 Froscio, M.B., 27:85  
 Fuchs, P.C., 28:27  
 Fujita, J.F., 28:53  
 Fuller, D.D., 29:219, 29:281
- Galanternik, L., 29:107  
 Garcia, A., 28:183  
 Garrison, M.W., 27:139  
 Gerding, D.N., 29:1  
 Giamarellos-Bourboulis, E.J., 29:81  
 Giamarelou, H., 29:81  
 Gonzalez, G., 28:183  
 Grecka, P., 29:81
- Grimm, H., 29:87  
 Gubbay, L., 29:29  
 Guelrud, M., 28:149
- Hackman, B.A., 28:1, 28:221  
 Hamilton, L., 27:123  
 Harris, S.L., 27:113  
 Hart, A.P., 29:139  
 Hartstein, A.I., 29:281  
 Hausler, W.J., Jr., 29:59  
 Hedderwick, S.A., 27:147  
 Hernandez, A., 27:17  
 Hill, D.S., 28:1  
 Hoban, D.J., 28:179, 29:5  
 Hoffman, M., 27:123  
 Hoffner, S.E., 28:119  
 Hojo, S., 28:53  
 Hollis, R.J., 27:63, 28:211, 29:95, 29:147, 29:187  
 Hoppe, J.E., 28:49  
 Houn, H.-S.H., 28:19  
 Hove, M.G.M., 28:41  
 Howard, W.J., 28:101  
 Hsieh, W.-C., 28:187  
 Hu, B.-S., 28:173  
 Hussong, J., 29:209
- Ichiyama, S., 28:53
- Jacobs, M.R., 27:75, 28:105, 28:131  
 James, O.A., 27:13  
 Jamjian, C., 27:129  
 Jarvis, W.R., 29:107  
 Jewesson, P., 29:155  
 Johnson, D.M., 28:139, 29:173  
 Johnson, S., 29:1  
 Jones, R.N., 27:1, 27:7, 27:21, 27:75, 27:93, 27:129, 27:151, 28:5, 28:35, 28:93, 28:101, 28:139, 28:157, 28:193, 28:209, 28:211, 29:43, 29:55, 29:87, 29:95, 29:119, 29:173, 29:187, 29:199, 29:241, 29:259, 29:265, 29:273  
 Jorgensen, J.H., 28:27
- Kabani, A.M., 28:179, 29:5  
 Kahn, J., 29:249  
 Kaplan, M.H., 28:123  
 Karlowsky, J.A., 28:179, 29:5  
 Kauffman, C.A., 27:147  
 Kaufman, S., 29:29  
 Kawanishi, K., 28:53  
 Kay, I.D., 28:75  
 Kenny, M.T., 27:107  
 Kessie, G., 27:69  
 Klepser, M.E., 29:227  
 Klym, K.A., 29:5  
 Knapp, C.C., 28:81  
 Koontz, F.P., 28:101  
 Korgenski, K., 27:123  
 Králiková, K., 29:129  
 Krcméry, V., Sr., 29:129  
 Krishna, S., 29:121

- Lara, D., 28:149  
 Larcom, L., 29:11  
 Lau, Y.-J., 28:173  
 Leahy, B.J., 28:75  
 Lee, P., 29:51  
 Legnani, D., 27:41  
 Lemes, M., 28:69  
 Lemmens, P., 28:165  
 LeMonte, A.M., 29:281  
 Lewno, M.J., 27:99  
 Lieberman, J.M., 29:73  
 Lin, Y.-H., 28:173  
 Lipson, S.M., 28:123  
 Liu, P.Y.-F., 28:173  
 Liu, P.Y.-K., 29:19  
 Lopardo, H., 29:107  
 Lopardo, H.A., 29:29  
 Lu, D.C.-T., 28:187  
 Ludwig, M.D., 28:81  
 Luh, K.-T., 28:187  
  
 Magalhães, M., 28:87  
 Malone, C.L., 27:139  
 Mann, L.M., 27:13  
 Marco, F., 29:55  
 Marin, M., 29:107  
 Marshall, S.A., 27:93, 28:35, 28:211, 29:43,  
 29:87, 29:95, 29:119, 29:187, 29:259, 29:273  
 Martin, S.J., 29:167  
 Mason, E.O., Jr., 27:99  
 Mauriz, Y., 29:249  
 McLaughlin, J.C., 29:139  
 Mella, S., 28:183  
 Mendes, C.M.F., 28:87  
 Messer, S.A., 29:147  
 Messick, C.R., 29:203  
 Michelangeli, F., 28:149  
 Miller, R., 29:111  
 Millesimo, M., 29:61  
 Miniça, I., 28:87  
 Miyawaki, H., 28:53  
 Mohammad, A.A., 27:13  
 Monroe, P., 27:123  
 Montgomerie, J.Z., 29:133, 29:233  
 Morera, C., 28:149  
 Morgan, M.B., 28:45  
 Morgan, S., 29:139  
 Mukantabana, B., 28:165  
 Munyabikali, J.P., 28:165  
  
 Nathan, C., 27:103  
 Negayama, K., 28:53  
 Nickoloff, D., 29:155  
 Nowakonski, A., 28:87  
  
 Obayashi, Y., 28:53  
 Ogilvie, P., 29:249  
 Okorodudu, A.O., 27:13  
  
 Palladino, S., 28:75  
 Pawsey, S.D., 28:201  
 Pearman, J.W., 28:75  
 Peery, R.B., 29:67  
  
 Pendland, S.L., 29:167, 29:203  
 Pérez, M.E., 28:149  
 Pérez-Cecilia, E., 29:193  
 Pericchi, L.R., 28:149  
 Personius, C.D., 28:205  
 Petersen, J.R., 27:13  
 Peterson, L.R., 29:209  
 Pezim, M., 29:155  
 Pfaller, M.A., 27:63, 27:75, 27:151, 28:65,  
 28:101, 28:157, 28:211, 29:43, 29:95, 29:147,  
 29:187, 29:199, 29:227, 29:259, 29:265, 29:  
 273  
 Plouffe, J.F., 28:1, 28:221  
 Poppiti, R.J., Jr., 28:69  
 Putnam, L.R., 28:101  
 Putnam, S.D., 28:139  
  
 Rainnie, B.J., 29:215  
 Rand, K.H., 27:55  
 Rao, L.V., 27:13  
 Reimer, L., 27:123  
 Reisner, B.S., 28:113  
 Reves, R.R., 28:45  
 Reynolds, D.L., 27:107  
 Rhomberg, P.R., 27:93  
 Rigby, E.W., 28:1  
 Robbie, L., 28:31  
 Romero, R., 28:149  
 Rosaenz, L., 29:29  
 Rose, M.J., 29:107  
 Rossi, F., 28:87  
  
 Sader, H.S., 28:87  
 Salazar, J.C., 29:265  
 Sánchez-Portocarrero, J., 29:193  
 Sarachian, B., 29:29  
 Saverio, S., 29:139  
 Savik, K., 29:1  
 Savoia, D., 29:61  
 Schaadt, R.D., 28:201  
 Schentag, J.J., 29:173  
 Schermer, I.H., 27:1  
 Schick, D.G., 29:233  
 Schreckenberger, P.C., 29:167  
 Schrock, J., 28:221  
 Schutze, G.E., 27:99  
 Schwab, U., 29:11  
 Schwartz, L., 29:155  
 Scilingo, V., 29:29  
 Segura, A.J.A., 28:87  
 Sethabutr, O., 28:19  
 Seymour, J., 29:133  
 Sharp, S.E., 28:69  
 Shepp, D.H., 28:123  
 Shi, Z.-Y., 28:173  
 Shimashita, J., 29:133  
 Skatrud, P.L., 29:67  
 Sleigh, K., 29:155  
 Smith, C.E., 27:85  
 Smith, J., 29:155  
 Smith, M.B., 27:113  
 Smith, M.D., 29:121  
 Soni, M., 28:123  
  
 Spardella, V., 28:149  
 Sparo, M., 29:29  
 Stalker, D.J., 28:201  
 Stevens, D.A., 29:103  
 Stiver, G., 29:155  
 Stoller, J., 29:155  
 Stone, B.L., 28:45  
 Stutman, H.R., 29:73  
 Sun, T., 28:123  
 Sura, T., 29:121  
 Swenson, J.M., 29:107  
  
 Takahara, J., 28:53  
 Takashima, C., 28:53  
 Tanabe, T., 28:53  
 Tenover, F.C., 28:27  
 Thornsberry, C., 29:249  
 Tobin, M.B., 29:67  
 Tokars, J.I., 29:107  
 Toršová, V., 29:129  
 Trombley, C., 28:61  
 Tsakris, A., 29:39  
 Tschirner, T., 28:49  
 Tuohy, M., 29:277  
 Tzouvelekis, L.S., 29:39  
  
 Vandepitte, J., 28:165  
 Vandeven, J., 28:165  
 Van Pelt, L., 29:111  
 Varnam, D., 28:93  
 Venuta, M.E., 29:29  
 Verhaegen, J., 28:165  
 Vezga, M.A., 28:149  
 Vidal, P., 29:29  
 Villaverde, P., 29:29  
 Visalli, M.A., 28:131  
  
 Wai, A., 29:155  
 Waites, K.B., 27:117  
 Walsh, A.L., 29:121  
 Washington, J.A., 27:75, 28:81, 29:277  
 Weems, J., 29:11  
 Wehr, C., 29:111  
 Weinstein, R.A., 27:103  
 Wennersten, C.B., 29:33  
 Wenzel, R.P., 28:211, 29:43, 29:95, 29:147,  
 29:259  
 White, N.J., 29:121  
 Wilke, W.W., 29:43, 29:95, 29:187  
 Wilson, M.L., 28:45  
 Woods, G.L., 27:17, 27:113, 28:41, 28:153  
 Wu, W.-L., 29:19  
  
 Yamaji, Y., 28:53  
 Yang, C., 28:65  
  
 Zelenitsky, S.A., 28:179  
 Zemelman, R., 28:183  
 Zerva, L., 28:35  
 Zhanel, G.G., 28:179, 29:5  
 Zhang, J., 27:63  
 Zimmer, B.L., 29:111  
 Zoccoli, C., 28:87  
 Zurenko, G.E., 28:201



## Subject Index to Volume 29

- Acid fast bacilli (AFB) smear, in pulmonary tuberculosis patient, 29:73-79
- Acinetobacter baumannii*
- Acinetobacter calcoaceticus* complex with, epidemiology of, 29:19-28
- pseudo-outbreak of, PCR testing in, 28:61-64
- third generation cephalosporins against, 28:183-186
- Acquired immune deficiency syndrome (AIDS) patients. *See also* Human immunodeficiency virus (HIV) infection
- fucospirochetal superinfection of oral lesion in, 29:51-53
- Mycobacterium avium* complex bacteremia diagnosis in, BACTEC 12B vs. solid media in, 28:41-43
- AFB (acid fast bacilli) smear, in pulmonary tuberculosis patient, 29:73-79
- AfuMDR1* and *AfuMDR2* genes, localization of, 29:67-71
- Agar dilution testing
- in *Bordetella parapertussis*, 28:49-51
- validation of, 27:1-5
- AIDS. *See* Acquired immune deficiency syndrome (AIDS) patients
- Alcaligenes xylosoxidans*, typing of, PCR vs. pulsed-field gel electrophoresis for, 28:173-178
- Amikacin
- against *Acinetobacter baumannii*, 28:183-186
- susceptibility testing of, 27:1-5
- Amikacin combinations, against *Pseudomonas aeruginosa*, 29:81-86
- Amoxicillin, *Haemophilus influenzae* resistance to, 28:105-112
- Amp C  $\beta$ -lactamase, blood stream infection-induced, SCOPE study of, 28:211-219
- Ampicillin
- chloramphenicol with and without, against vancomycin-resistant *Enterococcus* spp., 29:203-205
- levofloxacin with, against *Enterococcus faecium*, 27:85-92
- Ampicillin/sulbactam, susceptibility testing of, 28:5-18
- AMPLICOR
- in prison setting, 27:113-116
- reliability of, 27:17-20
- Animal food, avoparcin from, human antimicrobial spectrum and potency assessment of, 29:241-248
- Antifungal agents. *See also* specific agent
- Candida tropicalis* susceptibility to, 27:63-67
- growth medium effect on, 29:227-231
- with morpholine ring, 29:103-106
- Antimicrobial agents. *See also* specific agent
- against *Burkholderia cepacia*, 28:187-191
- oral, against respiratory tract infection, 27:21-28, 27:41-47
- prophylactic, after colorectal surgery, 29:155-165
- sustained action of, 27:21-28
- Antimicrobial susceptibility tests. *See also* specific agent; specific test
- of animal food glycopeptides, human antimicrobial spectrum and potency assessment of, 29:241-248
- correlation of, with MicroScan results, 29:111-120
- quinupristin/dalfopristin (Synercid) ratios in, 27:129-138
- validation of, 27:1-5, 27:93-97
- Antiviral susceptibility testing, flow cytometric analysis with, to detect cytomegalovirus drug resistance, 28:123-129
- Arbekacin, *Staphylococcus aureus* resistance to, nosocomial infection from, 28:53-59
- Argentina
- antimicrobial-resistant *Enterococcus* spp. detection in, 29:107-109
- Streptococcus pyogenes* in, penicillin and erythromycin susceptibility to, 29:29-32
- Aspergillus fumigatus*, molecular karyotype of, 29:67-71
- Avoparcin, human antimicrobial spectrum and potency assessment of, 29:241-248
- Azithromycin, antipneumococcal activity of, 28:131-137
- Aztreonam, susceptibility testing of, 27:1-5 with MicroScan, 29:111-120
- BACTEC
- for culture of sterile body fluids, 29:219-225
- in Enterobacteriaceae infection, 28:101-104
- in mycobacteria diagnosis, 28:41-43, 28:69-74
- Bacteremia, from *Mycobacterium avium* complex, BACTEC 12B vs. solid media diagnosis of, 28:41-43
- Bioassay, for rifapentine, 27:107-111
- BioStar Strep A optical immunoassay, comparison with other assays, 29:139-145
- Bio-Whittaker enzyme immunoassay
- in mumps virus, 28:31-34
- in varicella-zoster virus, 28:31-34
- Blastomyces* spp., BMS-181184 against, 28:179-182
- Blood, *Burkholderia cepacia* from, antimicrobial agents against, 28:187-191
- Blood stream infections
- Amp C  $\beta$ -lactamase production from, SCOPE study of, 28:211-219
- nosocomial
- enterococcal, 29:95-102
- non-enteric Gram-negative, broad-spectrum agents against, 29:187-192
- SCOPE study of, 29:95-102, 29:259-263
- species occurrence and antimicrobial resistance in, 29:259-263
- streptococcal, cefepime and ceftazidime against, 29:273-276
- BMS-181184, antifungal activity of, *in vitro*, 28:179-182
- Body fluids, sterile, culture of, BACTEC vs. other methods for, 29:219-225
- Book reviews
- Antibiotics in Laboratory Medicine*, 4th ed., V Lorian, 29:59
- Manual of Clinical Laboratory Immunology*, 5th ed., NR Rose, ED de Macario, JD Folds, HC Lane, RM Nakamura, 29:285
- Bordetella parapertussis*, Etest vs. agar dilution testing in, 28:49-51
- Brazil, cefepime effectiveness in, Etest evaluation of, 28:87-92
- Burkholderia cepacia*, antimicrobials alone and in combination against, 28:187-191
- Burkholderia pseudomallei*, PCR detection of, 29:121-127
- Burn unit, *Alcaligenes xylosoxidans* typing in, PCR vs. pulsed-field gel electrophoresis for, 28:173-178
- Canada, *Candida* spp. in, in tertiary care hospital, 29:5-9
- Candida* spp.
- BMS-181184 against, 28:179-182
- in Canadian tertiary care hospital, 29:5-9
- Candida (Torulopsis) glabrata*, identification of, 28:65-67
- Candida glabrata*, urinary, typing and fluconazole susceptibility of, 29:11-17
- Candida parapsilosis* outbreak, in prosthetic valve endocarditis, 29:147-153
- Candida tropicalis*, antifungal susceptibility of, 27:63-67
- CCFA (cycloserine-cefoxitin-fructose-agar), for isolation of *Clostridium difficile*, 29:1-4
- Cefdinir, susceptibility testing of, 27:1-5
- Cefepime
- Etest evaluation of, 28:87-92
- ethambutol synergistic antimycobacterial activity with, 28:119-122
- against streptococcal nosocomial blood stream infections, 29:273-276
- Cefotaxime, teicoplanin with, against Gram-positive bacteria, 29:87-94
- Cefprozil, susceptibility testing of, 27:1-5
- Ceftazidime
- amikacin with, against *Pseudomonas aeruginosa*, 29:81-86
- against streptococcal nosocomial blood stream infections, 29:273-276
- Cephalosporin(s)
- against *Acinetobacter baumannii*, 28:183-186
- Etest evaluation of, 28:87-92
- fifth generation catechol, 28:93-100

- pneumococcal resistance to, 27:99-101
- Cerebral mass lesions, in HIV-related cryptococcal meningitis, 29:193-198
- Chicago, multidrug resistant *Streptococcus pneumoniae* in, 29:209-214
- Children
- otitis media in, 27:35-39
  - sinusitis in, 27:35-39
- Chile, *Acinetobacter baumannii* in, third generation cephalosporins against, 28:183-186
- Chlamydia trachomatis*, PCR assay of, 28:75-79
- Christensen urease test, modification of, in *Helicobacter pylori* detection, 28:149-152
- Ciprofloxacin
- against *Acinetobacter baumannii*, 28:183-186
  - antipneumococcal activity of, 28:131-137
  - clarithromycin with and without, against *Legionella* spp., 29:167-171
  - Escherichia coli* resistance to, in rehabilitation center, 29:133-138
  - Neisseria gonorrhoeae* resistance to, trovafloxacin against, 28:187-191
- Clarithromycin
- antipneumococcal activity of, 28:131-137
  - against *Haemophilus influenzae*, pH and, 27:139-145
  - with and without ciprofloxacin or levofloxacin, against *Legionella* spp., 29:167-171
- Clavulanate, *Haemophilus influenzae* resistance to, 28:105-112
- Clostridium difficile*, isolation of, CCFA and taurocholate-CCFA in, 29:1-4
- Colombia,  $\beta$ -lactam drugs in, Etests of, 29:265-272
- Colorectal surgery, prophylactic antimicrobial regimens after, 29:155-165
- Community-acquired infections, respiratory, 27:41-47
- Contamination, in laboratory, *Mycobacterium avium* complex endocarditis from, 27:147-150
- CPS ID2 chromogenic agar, for urine culture, 28:113-117
- Cryptococcal meningitis, HIV-related, intracerebral mass lesions in, 29:193-198
- Cryptococcus* spp., BMS-181184 against, 28:179-182
- Cycloserine-cefoxitin-fructose-agar (CCFA), for isolation of *Clostridium difficile*, 29:1-4
- Cytomegalovirus, drug resistance of, antiviral susceptibility testing-flow cytometric analysis of, 28:123-129
- Disk-diffusion tests, of imipenem and meropenem, in oxacillin-resistant *Staphylococcus* spp., 28:81-86
- Endocarditis
- from *Mycobacterium avium* complex, laboratory cross-contamination in, 27:147-150
- prosthetic valve-related, *Candida parapsilosis* infection as, 29:147-153
- Endotracheal aspirates, from neonates, 27:55-61
- Enterobacteriaceae, Vitek system in, 28:35-40, 28:100-104
- Enterococcus* spp.
- antimicrobial-resistant, in Argentina, 29:107-109
  - in nosocomial blood stream infections, SCOPE study of, 29:95-102
  - RU-66647 against, 27:7-12
  - trovafloxacin against, 29:233-239
  - vancomycin-resistant, 29:43-49
  - chloramphenicol alone and with vancomycin, ampicillin, or RP 59500 against, 29:203-205
- Enterococcus faecium*, levofloxacin plus ampicillin against, 27:85-92
- Enterococcus raffinosus*, vancomycin-resistant, 29:43-49
- Eperezolid, serum inhibitory titers and bactericidal titers for, 28:201-204
- Epidemiological typing
- of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex, PCR vs. pulsed-field gel electrophoresis for, 29:19-28
  - of *Alcaligenes xylosoxidans*, PCR vs. pulsed-field gel electrophoresis for, 28:173-178
- EQUATE radioimmunoassay, of *Legionella pneumophila* urinary antigens, 28:1-3
- Erythromycin
- antipneumococcal activity of, 28:131-137
  - beta-hemolytic streptococcal resistance to, 27:123-128
  - Streptococcus pyogenes* susceptibility to, 29:29-32
- Escherichia coli*
- ciprofloxacin-resistant, in rehabilitation center, 29:133-138
  - enteroinvasive, PCR of, 28:19-25
  - PTZ resistance in, 29:39-41
- Etest
- of cefepime vs. cephalosporins, 28:87-92
  - of  $\beta$ -lactams, in Colombia, 29:265-272
  - of macrolides and quinolones, against *Legionella*, 28:221-223
  - in *Mycoplasma hominis*, 27:117-122
  - in *Neisseria meningitidis*, 27:93-97
  - of trovafloxacin, against *Neisseria gonorrhoeae*, 28:187-191
  - validation of, 27:1-5
  - in *Bordetella parapertussis*, 28:49-51
- Ethambutol, cefepime synergistic antimycobacterial activity with, 28:119-122
- Family practice setting, group A *Streptococcus* assays in, 29:139-145
- Fecal flora, preservation of, 27:103-106
- Feces, *Shigella* vs. *Escherichia coli* in, PCR of, 28:19-25
- Flow cytometric analysis, antiviral susceptibility testing with, to detect cytomegalovirus drug resistance, 28:123-129
- Fluconazole
- UR-9746 and UR-9751 vs., 29:103-106
- urinary *Candida glabrata* susceptibility to, 29:11-17
- Fluoroquinolones. See specific agent
- Fucospirochetal superinfection, of pre-existing oral lesion, in AIDS, 29:51-53
- Germany, Gram-positive bacteria in, teicoplanin combinations against, 29:87-94
- Gram-negative organisms
- cephalosporins vs. cefepime against, 28:87-92
  - meropenem against, 28:157-163
  - non-enteric, in nosocomial blood stream infection, broad-spectrum agents against, 29:187-192
- Gram-positive organisms
- cephalosporins vs. cefepime against, 28:87-92
  - meropenem against, 28:157-163
  - RU-66647 against, 27:7-12
  - teicoplanin combinations against, 29:87-94
- Greek hospital, *Escherichia coli* and *Klebsiella pneumoniae* in, PTZ resistance of, 29:39-41
- Group A Selective Strep Agar (ssA), comparison with other assays, 29:139-145
- Growth medium, antifungal activity and, 29:227-231
- Haemophilus influenzae*
- amoxicillin/clavulanate MICs of, 28:105-112
  - antimicrobial susceptibility tests in, 27:75-83
  - clarithromycin against, pH and, 27:139-145
  - $\beta$ -lactam resistance in, 27:21-28
  - $\beta$ -lactam-negative, in vertebral osteomyelitis, 28:204-208
  - multidrug-resistant, in United States respiratory season, 29:249-257
  - RU-66647 against, 27:7-12
- Helicobacter pylori*, modification of Christensen urease test in, 28:149-152
- $\beta$ -Hemolytic streptococci
- erythromycin-resistant, 27:123-128
  - $\beta$ -lactam drugs against, 27:151-154
- Hepatitis C virus, diagnosis of, in Saudi Arabia, 27:69-73
- High performance liquid chromatography assay, for rifapentine, 27:107-111
- Histoplasma capsulatum*, fungal culture incubation in, 28:41-43
- HIV infection. See Human immunodeficiency virus (HIV) infection
- Hospital
- Brazilian, cefepime effectiveness in, 28:87-92
  - Canadian tertiary, candidemia in, 29:5-9
  - Clostridium difficile* isolation in, CCFA and taurocholate-CCFA in, 29:1-4
  - Escherichia coli* and *Klebsiella pneumoniae* in, PTZ resistance of, 29:39-41
  - urinary *Candida glabrata* isolation in, fluconazole susceptibility of, 29:11-17



- Human immunodeficiency virus (HIV) infection  
 cryptococcal meningitis with, intracerebral mass lesions in, 29:193-198  
*Pneumocystis carinii* detection in, 29:61-65
- Imipenem  
 amikacin with, against *Pseudomonas aeruginosa*, 29:81-86  
 meropenem vs., *in vitro*, 28:157-163  
 against oxacillin-resistant staphylococci, 28:81-86
- Immuno-1 toxoplasma IgG assay, prenatal, 27:13-15
- Immunoblot assay, recombinant, of hepatitis C virus, 27:69-73
- Isoniazid, against *Mycobacterium tuberculosis*, 28:153-156
- Klebsiella pneumoniae*, PTZ resistance in, 29:39-41
- $\beta$ -Lactam drugs  
 against *Acinetobacter baumannii*, 28:183-186  
 Etests of, in Colombia, 29:265-272  
 ethambutol synergistic antimycobacterial activity with, 28:119-122  
 against *Haemophilus influenzae*, in vertebral osteomyelitis, 28:204-208  
 against  $\beta$ -hemolytic streptococci, 27:151-154  
 pharmacokinetics of, 27:29-33  
 resistance to, 27:21-28  
 against viridans group, 27:151-154
- $\beta$ -Lactamase, Amp C, blood stream infection-induced, SCOPE study of, 28:211-219
- Legionella* spp.  
 clarithromycin with and without ciprofloxacin or levofloxacin against, 29:167-171  
 macrolides and quinolones against, 28:221-223  
 trovafloxacin against, 29:55-57
- Legionella pneumophila*, urinary antigens against, stability of, 28:1-3
- Letter to the Editor, 29:111-120
- Levofloxacin  
 ampicillin with, against *Enterococcus faecium*, 27:85-92  
 antipneumococcal activity of, 28:131-137  
 antistreptococcal activity of, 29:199-201  
 clarithromycin with and without, against *Legionella* spp., 29:167-171
- Linezolid, serum inhibitory titers and bactericidal titers for, 28:201-204
- Liver disease, hepatitis C virus in, 27:69-73
- LY 303366, antifungal activity of, growth medium effect on, 29:227-231
- Macrolides, against *Legionella* spp., 28:221-223
- MDR-like genes, *AfuMDR1* and *AfuMDR2* as, 29:67-71
- Meningitis, cryptococcal, HIV-related, intracerebral mass lesions in, 29:193-198
- Meropenem  
 amikacin with, against *Pseudomonas aeruginosa*, 29:81-86  
 against oxacillin-resistant staphylococci, 28:81-86  
*in vitro* activity of, 28:157-163
- Methicillin, *Staphylococcus aureus* resistance to, nosocomial infection from, 28:53-59
- Microbroth dilution susceptibility tests of imipenem and meropenem, in oxacillin-resistant *Staphylococcus* spp., 28:81-86
- in *Mycoplasma hominis*, 27:117-122  
 in *Streptococcus pneumoniae*, 28:27-29
- MicroScan system, correlation of aztreonam susceptibility results with, 29:111-120
- Moraxella catarrhalis*  
 $\beta$ -lactam resistance in, 27:21-28  
 multidrug-resistant, in United States respiratory season, 29:249-257  
 RU-66647 against, 27:7-12
- Morpholine ring, antifungal agents with, 29:103-106
- Mueller-Hinton II agar dilution testing, in *Bordetella parapertussis*, 28:49-51
- Multidrug resistance, in *Streptococcus pneumoniae*  
 in Chicago, 29:209-214  
 in United States respiratory season, 29:249-257
- Mumps virus, Vidas and Bio-Whittaker enzyme immunoassays in, 28:31-34
- Mycobacterial growth indicator tube, to test isoniazid and rifampin against *Mycobacterium tuberculosis*, 28:153-156
- Mycobacterium avium* complex  
 BACTEC diagnosis of, 28:45-48, 28:69-74  
 bacteremia from, BACTEC 12B vs. solid media diagnosis of, 28:41-43  
 endocarditis from, laboratory cross-contamination in, 27:147-150
- Mycobacterium fortuitum-chelonae* complex, BACTEC vs. Septi-Chek AFB diagnosis of, 28:69-74
- Mycobacterium tuberculosis*  
 AMPLICOR identification of, 27:17-20  
 in prison setting, 27:113-116  
 BACTEC vs. Septi-Chek AFB diagnosis of, 28:69-74  
 isoniazid and rifampin against, 28:153-156
- Mycoplasma hominis*, tetracycline-resistant, 27:117-122
- Neisseria* spp., RU-66647 against, 27:7-12
- Neisseria gonorrhoeae*  
 DFA-negative, probe-positive, 29:281-283  
 trovafloxacin testing against, 28:187-191
- Neisseria meningitidis*, Etest validation in, 27:93-97
- Neonates, endotracheal aspirates from, 27:55-61
- Nosocomial infections  
 in blood stream  
 enterococcal, 29:95-102  
 non-enteric Gram-negative, broad-spectrum agents against, 29:187-192  
 SCOPE study of, 29:95-102, 29:259-263
- species occurrence and antimicrobial resistance in, 29:259-263  
 streptococcal, cefepime and ceftazidime against, 29:273-276
- Stenotrophomonas maltophilia* in, transferable antibiotic resistance to, 29:129-132
- stool studies of, preservatives in, 27:103-106
- Ofloxacin  
 antipneumococcal activity of, 28:131-137  
 teicoplanin with, against Gram-positive bacteria, 29:87-94
- Oral lesion, fucospirochetal superinfection of, in AIDS, 29:51-53
- Osteomyelitis, vertebral,  $\beta$ -lactamase-negative *Haemophilus influenzae* in, 28:204-208
- Otitis media, in children, 27:35-39
- Oxazolidinones, serum inhibitory titers and bactericidal titers for, 28:201-204
- PCR. See Polymerase chain reaction
- Penicillin  
 pneumococcal resistance to, 27:21-28  
*Streptococcus pyogenes* susceptibility to, 29:29-32
- Penicillin-binding proteins, pneumococcal alteration of, 27:21-28
- pH, clarithromycin activity and, in *Haemophilus influenzae*, 27:139-145
- Piperacillin/tazobactam (PTZ)  
*Escherichia coli* resistance to, 29:39-41  
*Klebsiella pneumoniae* resistance to, 29:39-41
- Pneumocystis carinii*, in HIV patient, 29:61-65
- Polymerase chain reaction  
 in *Acinetobacter baumannii* pseudo-outbreak, 28:61-64  
*Acinetobacter* spp. complex typing with, 29:19-28  
*Alcaligenes xylosoxidans* typing with, in burn unit, 28:173-178  
 in *Burkholderia pseudomallei* detection, 29:121-127  
 in *Chlamydia trachomatis*, 28:75-79  
 in fecal *Shigella* vs. *Escherichia coli*, 28:19-25  
 in hepatitis C virus, 27:69-73  
 in *Mycobacterium tuberculosis*, 27:17-20  
 in prison setting, 27:113-116  
 in pulmonary tuberculosis patient, 29:73-79
- Prenatal screening, for toxoplasmosis, 27:13-15
- Prevotella* spp., RU-66647 against, 27:7-12
- Prison, AMPLICOR *Mycobacterium tuberculosis* assay in, 27:113-116
- Prophylactic antimicrobial regimens, after colorectal surgery, 29:155-165
- Prosthetic valve endocarditis, *Candida parapsilosis* outbreak as, 29:147-153

- Pseudomonas aeruginosa*, amikacin combined with ceftazidime, meropenem, or imipenem against, 29:81-86
- Pseudomonas cepacia*. See *Burkholderia cepacia*
- PTZ. See Piperacillin/tazobactam (PTZ)
- Pulmonary tuberculosis, quantitative PCR, AFB smear and culture results in, 29:73-79
- Pulsed-field gel electrophoresis
- Acinetobacter* spp. complex typing with, 29:19-28
  - Alcaligenes xylosoxidans* typing with, in burn unit, 28:173-178
  - of DFA-negative, probe-positive *Neisseria gonorrhoeae*, 29:281-283
- Quinolones, against *Legionella* spp., 28:221-223
- Quinupristin/dalfopristin, chloramphenicol with and without, against vancomycin-resistant *Enterococcus* spp., 29:203-205
- Quinupristin/dalfopristin ratios, Synercid characteristics and, 27:129-138
- Radioimmunoassay, of *Legionella pneumophila* urinary antigens, 28:1-3
- Recombinant immunoblot assay diagnosis, of hepatitis C virus, 27:69-73
- Rehabilitation medical center, ciprofloxacin-resistance *Escherichia coli* in, 29:133-138
- Respiratory tract infections
- antimicrobial resistance in, 29:249-257
  - antimicrobials against, 29:33-38
  - sustained action of, 27:21-28
  - community-acquired, 27:41-47
  - future chemotherapies for, 27:49-53
  - trimethoprim alone vs. trimethoprim-sulfamethoxazole against, 29:33-38
- Rifampin, against *Mycobacterium tuberculosis*, 28:153-156
- Rifapentine, assays for, 27:107-111
- RP 59500, chloramphenicol with and without, against vancomycin-resistant *Enterococcus* spp., 29:203-205
- RPR 106972, antimicrobial activity and MIC quality control guidelines of, 28:139-147
- RU-59863, as fifth generation catechol cephalosporin, 28:93-100
- RU-66647
- action mechanisms of, 27:7-12
  - against *Enterococcus* spp., 27:7-12
- Rwanda, antibiotic resistance in, 28:165-171
- Salmonella* spp., in stool, selenite enrichment broth in detection of, 29:215-217
- Saudi Arabia, hepatitis C virus diagnosis in, 27:69-73
- SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) of blood stream infections
- Amp C  $\beta$ -lactamase induced by, 28:211-219
  - nosocomial enterococcal, 29:95-102
  - species occurrence and resistance, 29:259-263
- of vancomycin-resistant *Enterococcus raffi-nosus*, 29:43-49
- Selenite enrichment broth, to detect *Salmonella* spp. in stool, 29:215-217
- Septi-Chek AFB, in mycobacteria diagnosis, 28:69-74
- Shigella*
- antimicrobial resistance of, in Rwanda, 28:165-171
  - fecal, PCR of, 28:19-25
- Sinusitis, in children, 27:35-39
- SM-7738. See Meropenem
- Sparfloxacin
- antistreptococcal activity of, 29:199-201
  - broad spectrum activity of, 29:173-186
  - susceptibility testing of, 27:1-5
- Staphylococcus* spp., 27:7-12
- oxacillin-resistant, imipenem and meropenem against, 28:81-86
- Staphylococcus aureus*, arbekacin- and methicillin-resistant, nosocomial infection from, 28:53-59
- Stenotrophomonas maltophilia*, nosocomial, transferable antibiotic resistance to, 29:129-132
- Sterile body fluids, culture of, BACTEC vs. other methods for, 29:219-225
- Stool studies
- nosocomial, preservatives in, 27:103-106
  - Salmonella* detection in, selenite enrichment broth for, 29:215-217
- Streptococcus* spp.
- group A, comparison of assays for, 29:139-145
  - $\beta$ -hemolytic, erythromycin-resistant, 27:123-128
  - in nosocomial blood stream infections, cefepime and ceftazidime against, 29:273-276
  - viridans group, antimicrobial susceptibility of, 29:277-280
- Streptococcus pneumoniae*
- cephalosporin-resistant, 27:99-101
  - levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin against, 28:131-137
  - microbroth dilution susceptibility tests in, 28:27-29
  - multidrug-resistant, 29:209-214
  - in Chicago, 29:209-214
  - in United States respiratory season, 29:249-257
  - penicillin-resistant, 27:21-28
- Streptococcus pyogenes*, penicillin and erythromycin susceptibility to, 29:29-32
- Streptogramin combination, oral, 28:139-147
- Sulfonamide intolerance, trimethoprim alone in, for upper respiratory tract infections, 29:33-38
- Synercid, quinupristin/dalfopristin ratios in, 27:129-138
- Taurocholate-CCFA, for isolation of *Clostridium difficile*, 29:1-4
- Teicoplanin, cefotaxime or ofloxacin with, against Gram-positive bacteria, 29:87-94
- Tetracycline, *Mycoplasma hominis* resistance to, 27:117-122
- Tobramycin, susceptibility testing of, 27:1-5
- Todd-Hewitt broth cultures, comparison with other assays, 29:139-145
- Toxoplasmosis, prenatal screening for, Immuno-1 assay in, 27:13-15
- Trimethoprim, alone and with sulfamethoxazole, for upper respiratory tract infections, 29:33-38
- Trovafloxacin
- against *Enterococcus* spp., 29:233-239
  - against *Legionella* spp., 29:55-57
  - against *Neisseria gonorrhoeae*, 28:187-191
- Tuberculosis, pulmonary, quantitative PCR, AFB smear and culture results in, 29:73-79
- United States
- erythromycin-resistant streptococcus in, 27:123-128
  - Gram-positive organisms in, teicoplanin combinations against, 29:87-94
  - Haemophilus influenzae* in
    - antimicrobial susceptibility tests in, 27:75-83
    - multidrug-resistant, 29:249-257  - Moraxella catarrhalis* in, multidrug-resistant, 29:249-257
  - multidrug-resistant *Streptococcus pneumoniae* in, 29:209-214, 29:249-257
  - sparfloxacin activity and spectrum assessments in, 29:173-186
  - vancomycin-resistant *Enterococcus raffi-nosus* in, 29:43-49
- UR-9746 and UR-9751, fluconazole vs., 29:103-106
- Urine, *Candida glabrata* in, typing and fluconazole susceptibility of, 29:11-17
- Urine culture, CPS ID2 chromogenic agar for, 28:113-117
- Vancomycin, *Enterococcus* resistance to, 29:43-49
- chloramphenicol alone and with vancomycin, ampicillin, or RP 59500 against, 29:203-205
- Varicella-zoster virus, Vidas and Bio-Whittaker enzyme immunoassays in, 28:31-34
- Vertebral osteomyelitis,  $\beta$ -lactamase-negative *Haemophilus influenzae* in, 28:204-208
- Vidas enzyme immunoassay
- in mumps virus, 28:31-34
  - in varicella-zoster virus, 28:31-34
- Viridans group
- antimicrobial susceptibility of, 29:277-280
  - $\beta$ -lactam drugs against, 27:151-154
- Vitek GNS-F6 card, validity of, in Enterobacteriaceae, 28:35-40
- World wide pathogens, meropenem against, 28:157-163



